Krystal Biotech, Inc. Stock 12‑Month Price Target Raised to $395.44, Implies 20% Upside
Analysts raised Krystal Biotech's 12-month price target from $392.11 to $395.44, suggesting 20% upside. The consensus rating remains 'Buy' with 12 Buys, 1 Hold, and 0 Sells.
How this was made
The 30-second read
Why it matters
This is primarily a sentiment/expectations update. Without new operational or clinical milestones, it is more likely to affect positioning and short-term narrative than to drive a durable repricing.
Market read
Traders may treat the higher consensus target as a modest bullish input, but the lack of new fundamentals limits trading edge.
What to watch
The article does not specify which analysts changed targets, the rationale, or whether any near-term catalysts (trial readouts, approvals, guidance) are imminent.
Background
The article summarizes FactSet-based consensus analyst price targets and ratings for Krystal Biotech.
Ticker impact
Krystal Biotech’s average analyst price target rose from $392.11 to $395.44, with consensus rating staying “Buy” across 13 analysts.
Likely mild upward bias as traders price in the updated consensus target, with limited follow-through absent new company-specific news.
The piece is an analyst-target update (FactSet-derived) with no accompanying earnings, guidance, trial, or corporate action disclosed.
Market effects
Minimal sector read-through because this is a single-name analyst target adjustment without new biotech-specific data.
No clear regional spillover implied.
Limited global relevance; this is a US-listed single-company estimate update.
Counterpoint
Price-target increases may reflect model recalibration rather than new information, so the stock may not move much if fundamentals have not changed.
Key entities
- companyKrystal Biotech, Inc.
Subject of the article, with consensus price target and rating updates reported.
